Strides to divest Australian business Arrow

31 January 2019 - Deborah Wilkes

Premium

Strides Pharma Science is selling its Australian business Arrow Pharmaceuticals to the Arrow-Apotex merged entity in a deal worth AUD394 million (USD285 million).

Annual Subscription Holder?

Sign in to continue reading.
 

Sign In

Back to Industry News

Share this page: